EUCTR2016-004867-38-NL
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Autolus Limited
- Enrollment
- 500
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients must have received an AUTO CAR T cell therapy on a clinical treatment study.
- •Patients must have provided informed consent for long\-term follow\-up study prior to participation.
- •Patients must be able to comply with the study requirements.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 39
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 169
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 292
Exclusion Criteria
- •\- There are no specific exclusion criteria for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.CTIS2024-511684-28-00Autolus Limited111
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapyEUCTR2016-004867-38-GBAutolus Limited500
Withdrawn
Phase 2
ong-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors.Plasma Cell Neoplasm, Lymphomas non-Hodgkin's B-cell, Lymphomas non-Hodgkin's T-cell and LeukaemiasCancer10024324NL-OMON46028Autolus Limited32
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-000297-38-BEInstitut de Recherches Internationales Servier (I.R.I.S)200
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-000297-38-FRInstitut de Recherches Internationales Servier (I.R.I.S)200